These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1689 related articles for article (PubMed ID: 8238183)

  • 41. Clinical and hormonal effects of ethinylestradiol combined with gestodene and desogestrel in young women with acne vulgaris.
    Mango D; Ricci S; Manna P; Miggiano GA; Serra GB
    Contraception; 1996 Mar; 53(3):163-70. PubMed ID: 8689881
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term treatment of hirsutism: desogestrel compared with cyproterone acetate in oral contraceptives.
    Porcile A; Gallardo E
    Fertil Steril; 1991 May; 55(5):877-81. PubMed ID: 1827074
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 micrograms desogestrel and either 30 micrograms or 20 micrograms ethinyl oestradiol.
    Akerlund M; Røde A; Westergaard J
    Br J Obstet Gynaecol; 1993 Sep; 100(9):832-8. PubMed ID: 8218004
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism.
    Oelkers W; Foidart JM; Dombrovicz N; Welter A; Heithecker R
    J Clin Endocrinol Metab; 1995 Jun; 80(6):1816-21. PubMed ID: 7775629
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical comparison of two low-dose oral contraceptives, Minulet and Mercilon, in women over 30 years of age.
    Kirkman RJ; Pedersen JH; Fioretti P; Roberts HE
    Contraception; 1994 Jan; 49(1):33-46. PubMed ID: 8137624
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hemostatic and metabolic effects of lowering the ethinyl-estradiol dose from 30 mcg to 20 mcg in oral contraceptives containing desogestrel.
    Basdevant A; Conard J; Pelissier C; Guyene TT; Lapousterle C; Mayer M; Guy-Grand B; Degrelle H
    Contraception; 1993 Sep; 48(3):193-204. PubMed ID: 8222650
    [TBL] [Abstract][Full Text] [Related]  

  • 47. New progestogens in oral contraceptives.
    Runnebaum B; Rabe T
    Am J Obstet Gynecol; 1987 Oct; 157(4 Pt 2):1059-63. PubMed ID: 2960242
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Oral contraceptive and postmenopausal estrogen effects on lipoprotein triglyceride and cholesterol in an adult female population: relationships to estrogen and progestin potency.
    Knopp RH; Walden CE; Wahl PW; Hoover JJ; Warnick GR; Albers JJ; Ogilvie JT; Hazzard WR
    J Clin Endocrinol Metab; 1981 Dec; 53(6):1123-32. PubMed ID: 7298796
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Oral contraceptives containing 20 or 30 micrograms ethinylestradiol and 150 micrograms desogestrel: pharmacokinetics and pharmacodynamic parameters.
    Jung-Hoffmann C; Fitzner M; Kuhl H
    Horm Res; 1991; 36(5-6):238-46. PubMed ID: 1823082
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Progestins and oral contraceptive-induced lipoprotein changes: a prospective study.
    Lipson A; Stoy DB; LaRosa JC; Muesing RA; Cleary PA; Miller VT; Gilbert PR; Stadel B
    Contraception; 1986 Aug; 34(2):121-34. PubMed ID: 3096633
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ovarian activity during regular oral contraceptive use.
    Crosignani PG; Testa G; Vegetti W; Parazzini F
    Contraception; 1996 Nov; 54(5):271-3. PubMed ID: 8934059
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of efficacy, cycle control, and tolerability of two low-dose oral contraceptives in a multicenter clinical study.
    Endrikat J; Düsterberg B; Ruebig A; Gerlinger C; Strowitzki T
    Contraception; 1999 Nov; 60(5):269-74. PubMed ID: 10717778
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Time-dependent alterations in lipid metabolism during treatment with low-dose oral contraceptives.
    Kuhl H; März W; Jung-Hoffmann C; Heidt F; Gross W
    Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):363-9. PubMed ID: 2142576
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of desogestrel on carbohydrate metabolism.
    Shoupe D
    Am J Obstet Gynecol; 1993 Mar; 168(3 Pt 2):1041-7. PubMed ID: 8447358
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Influence of progestins on adverse effects of oral contraceptives].
    Wynn V
    Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):425-30. PubMed ID: 12280210
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effect of a desogestrel-containing oral contraceptive on glucose tolerance and leptin concentrations in hyperandrogenic women.
    Nader S; Riad-Gabriel MG; Saad MF
    J Clin Endocrinol Metab; 1997 Sep; 82(9):3074-7. PubMed ID: 9284746
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A comparative randomized trial on the impact of two low-dose oral contraceptives on ovarian activity, cervical permeability, and endometrial receptivity.
    Rossmanith WG; Steffens D; Schramm G
    Contraception; 1997 Jul; 56(1):23-30. PubMed ID: 9306028
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical and metabolic considerations of long-term oral contraceptive use.
    Godsland IF; Crook D; Wynn V
    Am J Obstet Gynecol; 1992 Jun; 166(6 Pt 2):1955-63. PubMed ID: 1605285
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Changes in androgens during treatment with four low-dose contraceptives.
    Coenen CM; Thomas CM; Borm GF; Hollanders JM; Rolland R
    Contraception; 1996 Mar; 53(3):171-6. PubMed ID: 8689882
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A comparative study of the effects of the hemostatic system of two monophasic gestodene oral contraceptives containing 20 micrograms and 30 micrograms ethinylestradiol.
    Winkler UH; Schindler AE; Endrikat J; Düsterberg B
    Contraception; 1996 Feb; 53(2):75-84. PubMed ID: 8838483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 85.